Exhibit 99.2
Deep Insights,Impactful Medicines
Disclaimers
Patients with Type 2 and 3 SMA Continue to Experience Major Functional Deficits Despite Improvement from SMN Therapy*
Non-Ambulatory Type 2/3 SMA: Majority of Patients Started on SMN Rx After Age 5 Do Not Experience Motor Function Increases*
Safety Results from TOPAZ 12-Month Top-Line Analysis Support Evaluation of Apitegromab in Phase 3 Trial
SAPPHIRE Phase 3 Design Optimized by Insights from TOPAZ
SAPPHIRE Phase 3 Design Optimized by Insights from TOPAZ
TOPAZ Age 2-12 Exploratory Analysis(Non-Ambulatory Type 2/3 SMA)
TOPAZ Age 2-12 Analysis* in Pooled Non-Ambulatory Cohorts Transformative Potential as Add-on for Apitegromab
SAPPHIRE (Phase 3) Trial Overview
Significant Interest in Potential Role of TGFβ Inhibition in Immuno-Oncology
Emerging Evidence Implicates TGFβ1 as Driving Primary Resistance to Checkpoint Inhibitors
SRK-181: Unique TGFβ1-Selective Approach to Overcoming Checkpoint Inhibitor Resistance
TGFβ1 Blockade with SRK-181-mIgG1 Rendered Preclinical Tumor Models Susceptible to Anti-PD1 Therapy
TGFβ1 Isoform Specificity of SRK-181 Improved Preclinical Toxicity Profile
SRK-181 Therapeutic Hypothesis: Potential Advantages of Latent TGFβ1 Inhibitor
DRAGON Phase 1 POC Trial to Evaluate SRK-181’s Ability to Overcome Primary Resistance to Checkpoint Inhibitors
DRAGON Part A: Dose Escalation Update and Safety Data
DRAGON Part A: Preliminary Pharmacokinetics (PK) Summary of SRK-181
DRAGON Part A: Preliminary Anti-Tumor Effects*
DRAGON Has Advanced to Part B to Test Proof of Concept for SRK-181 in Overcoming Anti-PD-(L)1 Resistance
Appendix
Apitegromab: Pairing the latent form with important translational insights
Apitegromab: Muscle-Directed Therapy Aimed at Complementing SMN Upregulators
Apitegromab Phase 2 Trial Design
Baseline CharacteristicsNusinersen-treated patients well into chronic maintenance phase
Non-Ambulatory Type 2 Cohort: Initiated nusinersen age <5
Non-Ambulatory Type 2/3 Cohort: Initiated nusinersen age ≥5
Majority of Ambulatory Patients Maintained or Improved in RHS Score from Baseline
Pharmacokinetic and Pharmacodynamic Data are Supportive of Clinically Observed Effects
Increases in HFMSE Not Correlated with Duration of Prior Nusinersen Treatment
WHO Motor Development Milestone Achievements Further Support Apitegromab’s Potential to Improve Motor Function
Inhibition of TGFβ1: Multipronged Approach for Immuno-Oncology
TGFβ1 Blockade with SRK-181-mIgG1 Rendered Preclinical Tumor Models Susceptible to Anti-PD1 Therapy